These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8105940)

  • 21. Frusemide therapy and intact parathyroid hormone plasma concentrations in chronic renal insufficiency.
    Reichel H; Deibert B; Geberth S; Schmidt-Gayk H; Ritz E
    Nephrol Dial Transplant; 1992; 7(1):8-15. PubMed ID: 1316586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion.
    Reginster JY; Zegels B; Lejeune E; Micheletti MC; Taquet AN; Albert A
    Gynecol Endocrinol; 2001 Feb; 15(1):56-62. PubMed ID: 11293926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations.
    Martin KJ; Ballal HS; Domoto DT; Blalock S; Weindel M
    Am J Kidney Dis; 1992 Jun; 19(6):540-5. PubMed ID: 1595702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
    Murakami K; Miyachi H; Watanabe A; Kawamura N; Fujii M; Koide S; Murase M; Kushimoto H; Hasegawa M; Tomita M; Hiki Y; Sugiyama S
    Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism, improve arterial stiffness in patients on continuous ambulatory peritoneal dialysis?
    Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M; Uchida K
    Adv Perit Dial; 2011; 27():134-9. PubMed ID: 22073845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of calcitriol pulse therapy per os in CAPD patients.
    Scanziani R; Dozio B; Bonforte G; Surian M
    Adv Perit Dial; 1994; 10():270-4. PubMed ID: 7999844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.
    Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H
    Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
    Coronel F; Rodríguez-Cubillo B; Cigarrán S; Gomis A
    Adv Perit Dial; 2011; 27():130-3. PubMed ID: 22073844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of secondary hyperparathyroidism in the patients undergoing hemodialysis--focused on parathyroid hormone assay system].
    Watanabe Y; Yuzawa Y; Mizumoto D; Itoh Y; Itoh A; Yamazaki C
    Rinsho Byori; 1992 Oct; 40(10):1014-20. PubMed ID: 1339162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
    Rapoport J; Mostoslavski M; Ben-David A; Knecht A; Blau A; Arad J; Zlotnik M; Chaimovitz C
    Nephron; 1996; 72(2):150-4. PubMed ID: 8684518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Testa S; Claris-Appiani A; Mehls O
    Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.
    Ritz E; Matthias S; Seidel A; Reichel H; Szabo A; Hörl WH
    Kidney Int Suppl; 1992 Oct; 38():S37-42. PubMed ID: 1405379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.
    Teruel JL; Tenorio MT; Rodríguez JR; Marc n R; Orofino L; Rivera M; Ortuño J
    Am J Nephrol; 1999; 19(3):428-32. PubMed ID: 10393383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal pulse calcitriol in the treatment of secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
    Chan HW; Tsang WK; Chan CM; Fung SK; So SO; Tang HL; Tong MK; Lee KC; Chan AY
    Perit Dial Int; 1998; 18(2):177-82. PubMed ID: 9576366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients.
    Bechtel U; Mücke C; Feucht HE; Schiffl H; Sitter T; Held E
    Am J Kidney Dis; 1995 Feb; 25(2):291-6. PubMed ID: 7847357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia.
    Brandi L; Daugaard H; Egsmose C; Tvedegaard E; Kjaerulff Nielsen P; Olgaard K
    J Intern Med; 1996 Apr; 239(4):353-60. PubMed ID: 8774390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTH levels correlate with mental performance in CAPD.
    Garcia-Maldonado M; Patterson D; Smith ZM
    Adv Perit Dial; 1991; 7():234-6. PubMed ID: 1680433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio.
    Fehmi H; Osman Y; Bhat S; Nguyen K; Daramola O; Cantor T; Monier-Faugere MC; Yee J; Malluche HH
    Clin Nephrol; 2009 Mar; 71(3):267-75. PubMed ID: 19281737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.